Bairen Medical (688198.SH): Collagen implant product approved for registration. It is the first collagen product in China to be injected into the dermal layer of the cheek to improve the smoothness of the cheeks

Zhitong Financial App News, Bairen Medical (688198.SH) issued an announcement. Recently, after review by the State Drug Administration, the company's holding subsidiary Beijing Abirui Biotechnology Co., Ltd.'s registration application for collagen implant products (i.e. collagen fiber filler-I) was approved. This is the first collagen product in China to be injected into the dermal layer of the cheek to improve the smoothness of the cheeks.

This product is a natural cross-linked complete type I collagen fiber (Collagen Fibers & Fibers), which has a stable three-stranded helix structure and is spontaneously assembled into an orderly fibrous supramolecular structure. The implantation of this product can supplement the skeletal collagen in the cheek dermal layer to improve extracellular interstitial metabolism, give facial skin better tissue texture and viscoelasticity, and reproduce the original tissue elasticity and luster.

The innovative technology of this product includes a proprietary ultra-pure extraction process and precise removal of terminal peptides to achieve consistent amino acid residue sequence and composition with the primary structure of human type I collagen, and humanize the product at the molecular level. Clinical trials have proven that there is no difference in immunogenicity from natural human collagen. Since this product is a full-length collagen molecule, the integrity of its three-helix structure is ensured; at the same time, the high purity satisfies the spontaneous assembly of the product into collagen fibers, making this product different in structure and quality from similar injectable collagen in the past.

The core technology of this product stems from the company's many years of technology accumulation in the field of collagen. It was successfully launched by the company's R&D center's molecular biology and biochemistry laboratory, laying the foundation for future full-length quantitative crosslinking of collagen II and collagen III based on ribose crosslinking; at the same time, it provides ultra-pure full-length collagen for the development of products such as split interventional valve anchoring stents, aortic root expansion patches, and tissue therapy to achieve the functional use of implantation materials. The launch of this product is another landmark achievement of the company's original research and innovation platform for animal-derived interventional materials, fully demonstrating the advantages of the company's platform-based operation.